Last Update 25 Mar 26

TNG: Phase I Head And Neck Data Will Drive Future Repricing

Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset.

What's in the News

Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).
The preprint reports 100% two year disease free survival for patients treated with TG4050 as monotherapy in the adjuvant setting for operable head and neck cancers, based on the Phase I data set described (medRxiv preprint).
Translational data in the preprint indicate that TG4050 induced neoantigen specific T cell responses in 73% of 15 evaluable patients, with markers of cytotoxic and effector phenotypes observed up to one year after treatment ended (medRxiv preprint).
The TG4050 manuscript has been submitted to a peer reviewed journal and is under evaluation. The randomized Phase I/II trial in head and neck squamous cell carcinoma continues under clinical identifier NCT04183166 (company announcement).
Transgene highlights TG4050 as the lead asset on its myvac platform and references additional viral vector based programs, including BT-001, an oncolytic virus built on the Invir.IO backbone. The company also notes broader discovery and preclinical work in immunotherapies in partnership with NEC for mutation selection using Artificial Intelligence (company materials).

Valuation Changes

Fair Value: €1.1 per share is unchanged, indicating a stable central estimate for the equity valuation.
Discount Rate: The discount rate has risen slightly from 6.66% to 6.68%, reflecting a marginal adjustment to the risk and return assumptions used in the model.
Revenue Growth: The long term revenue growth assumption remains effectively flat at a 7.84% decline, with only a very small technical adjustment to the input.
Net Profit Margin: The projected net profit margin is essentially unchanged at around 35.40%, with the update reflecting only a rounding level shift.
Future P/E: The forward P/E multiple has risen slightly from 83.93x to 83.97x, a minimal move that keeps the valuation framework broadly consistent with prior work.

0 views

Key Takeaways

Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.
Enhanced manufacturing capabilities are expected to improve net margins by reducing costs and increasing efficiency.
Uncertainty from missed trial objectives and strategic delays, alongside reliance on external funding, could challenge Transgene's revenue growth and financial stability.

Catalysts

About Transgene

A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.What are the underlying business or industry changes driving this perspective?

The progression to a Phase II trial for TG4050, an individualized therapeutic cancer vaccine, could boost future revenue by establishing Transgene as a key player in the neoantigen therapeutic cancer vaccine market.
The expected presentation of 24-month follow-up data and long-term immunogenicity data for TG4050 in 2025 might enhance Transgene's reputation and validation, potentially increasing revenue as the data could support further development and partnerships.
Initiating a new Phase I trial for TG4050 in a second indication expected in Q4 2025 presents a growth opportunity in expanding the use of their myvac platform, potentially impacting revenue streams positively by entering additional markets.
Significant advancements in manufacturing capabilities, aiming for a rapid, integrated, and scalable process, are likely to improve net margins by reducing production costs and increasing efficiency as the program advances.
Additional data releases from other pipeline assets like TG4001 and BT-001 scheduled for 2025 could drive revenue growth by demonstrating positive outcomes in treating specific cancer types and supporting potential new treatment indications.

Transgene Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Transgene's revenue will decrease by 7.8% annually over the next 3 years.
Analysts are not forecasting that Transgene will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Transgene's profit margin will increase from -485.6% to the average GB Biotechs industry of 35.4% in 3 years.
If Transgene's profit margin were to converge on the industry average, you could expect earnings to reach €2.1 million (and earnings per share of €0.02) by about March 2029, up from -€36.8 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 84.3x on those 2029 earnings, up from -5.5x today. This future PE is greater than the current PE for the GB Biotechs industry at 12.9x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.68%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The TG4001 trial did not meet its primary objective for progression-free survival in the overall patient population, which could dampen investor confidence and negatively impact future revenue expectations.
The challenges associated with intravenous administration of TG6050, including potential neutralization by the patient’s immune system, may limit its efficacy and could result in higher-than-anticipated development costs, impacting net margins.
The final strategy for BT-001 has not yet been defined, introducing uncertainty about the asset's future prospects and its potential impact on Transgene's revenue growth.
Delays or extensions in trial timelines, such as the 2027 completion date for TG4050 Phase II efficacy analysis, may lead to increased operational costs and delay revenue recognition, affecting earnings.
Dependence on partnerships and external funding, as evidenced by the credit facility from TSGH, may indicate potential cash flow issues that could affect the company’s financial stability beyond April 2026.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €1.1 for Transgene based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €5.9 million, earnings will come to €2.1 million, and it would be trading on a PE ratio of 84.3x, assuming you use a discount rate of 6.7%.
Given the current share price of €0.74, the analyst price target of €1.1 is 32.4% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Transgene?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines